Research
-
Understanding a molecular mechanism as a cause of retinitis pigmentosa
Exploring the molecular mechanism of a new cause of autosomal dominant retinitis pigmentosa and potential therapies.
ActiveJune 2020 - October 2024 -
Optogenetic therapy with CRISPR-assisted activation of rhodopsin
ActiveJanuary 2024 - December 2026 -
Investigating alternative genetic causes of Retinitis Pigmentosa
The aim of the project is to understand if alterations in a gene called ARL13B, are present in patients with retinitis pigmentosa (RP), and to characterise how those alterations affect retinal cells.
CompletedJune 2022 - September 2022 -
Making a vital component of gene therapy for retinitis pigmentosa that can be used in clinical trials
Improving on a treatment that works well in animals with a natural form of severe sight loss
CompletedOctober 2013 - September 2016 -
Developing a safe 'designer drug' to correct the genetic faults behind inherited eye disorders
A clever approach to treatment that could potentially restore sight
CompletedDecember 2013 - December 2016 -
Can we repair ‘misfolding’ proteins in a common type of retinitis pigmentosa?
Looking for substances that can make the light-detecting pigment rhodopsin more stable.
CompletedOctober 2014 - September 2018 -
How does scarring in the retina affect the chances of successful cell replacement therapy?
A look at the differences between inherited eye disorders
CompletedOctober 2015 - December 2017 -
Ensuring safety of channelrhodopsin optogenetic therapies for vision restoration
Starting soonSeptember 2024 - September 2027 -
Improving healthcare services for people with inherited retinal dystrophies: an evidence-based approach.
A research programme to reduce inequality, provide information and increase the options open to patients and families
CompletedJanuary 2010 - March 2016